Want to see IRTC full AI Analyst Report?
IRTC Stock Chart & Stats
$125.32
-$0.21(-0.23%)
At close: 4:00 PM EST
$125.32
-$0.21(-0.23%)
Day’s Range― - ―
52-Week Range$100.85 - $212.00
Previous CloseN/A
Volume94.23K
Average Volume (3M)594.28K
Market Cap
$3.87B
Enterprise Value$3.83B
Total Cash (Recent Filing)$549.62M
Total Debt (Recent Filing)$729.29M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Jul 30, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.86
Shares Outstanding32,862,408
10 Day Avg. Volume649,725
30 Day Avg. Volume594,285
Financial Highlights & Ratios
PEG Ratio2.07
Price to Book (P/B)37.18
Price to Sales (P/S)7.60
P/FCF Ratio164.50
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue4.87
Enterprise Value/Gross Profit6.85
Enterprise Value/Ebitda304.40
Forecast
1Y Price Target
$176.45Price Target Upside40.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$881.04M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue Growth And Strong Gross MarginsConsistent multi-year revenue expansion to ~$788M TTM and stable ~70% gross margins indicate durable unit economics and scale benefits. High gross margins provide structural profitability leverage as volume grows, supporting long-term margin improvement and reinvestment capacity.
Improved Cash Generation And Positive Operating Cash FlowThe company transitioned from negative to positive operating cash flow and positive FCF in the TTM period, a structural improvement that increases self-funding ability for R&D, commercialization and international expansion. This reduces reliance on external financing long-term.
Unique Data Assets, Clinical Adoption And AI RoadmapA massive proprietary ECG dataset, strong clinical publication support and deep EHR integrations create a durable competitive moat. Regulatory-cleared AI and workflow automation can materially cut review costs, raise throughput and sustain higher margins as adoption scales.
Bears Say
High Financial LeverageElevated leverage (~4.5x debt-to-equity) constrains balance-sheet flexibility and increases sensitivity to execution and interest-rate risk. High debt magnifies downside from operational setbacks and limits optionality for M&A or large strategic investments over the medium term.
GAAP Profitability Still NegativeDespite meaningful EBITDA improvement, GAAP net losses persist, meaning accrual-based profitability and retained‑earnings deficits remain. Continued losses can restrict long-term capital allocation, reduce retained capital for growth, and prolong dependence on external funding if cash inflection stalls.
Regulatory, Litigation And Coverage UncertaintyOpen FDA/DOJ reviews and proposed LCD changes create structural uncertainty around approval timing, compliance costs and reimbursement classification. Adverse policy or regulatory outcomes could materially alter addressable market economics and slow provider adoption over multiple quarters.
Irhythm Technologies News
IRTC FAQ
What was Irhythm Technologies’s price range in the past 12 months?
Irhythm Technologies lowest stock price was $100.84 and its highest was $212.00 in the past 12 months.
What is Irhythm Technologies’s market cap?
Irhythm Technologies’s market cap is $3.87B.
When is Irhythm Technologies’s upcoming earnings report date?
Irhythm Technologies’s upcoming earnings report date is Jul 30, 2026 which is in 18 days.
How were Irhythm Technologies’s earnings last quarter?
Irhythm Technologies released its earnings results on Apr 30, 2026. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.659 by $0.229.
Is Irhythm Technologies overvalued?
According to Wall Street analysts Irhythm Technologies’s price is currently Undervalued.
Does Irhythm Technologies pay dividends?
Irhythm Technologies does not currently pay dividends.
What is Irhythm Technologies’s EPS estimate?
Irhythm Technologies’s EPS estimate is -0.05.
How many shares outstanding does Irhythm Technologies have?
Irhythm Technologies has 32,862,408 shares outstanding.
What happened to Irhythm Technologies’s price movement after its last earnings report?
Irhythm Technologies reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.659. Following the earnings report the stock price went down -6.473%.
Which hedge fund is a major shareholder of Irhythm Technologies?
Currently, no hedge funds are holding shares in IRTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Irhythm Technologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$176.45 (40.80% Upside)
$176.45 (40.80% Upside)
Blogger Sentiment
Bullish
IRTC Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $678.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.26%
12-Months-Change
Fundamentals
Return on Equity
-20.60%
Trailing 12-Months
Asset Growth
8.67%
Trailing 12-Months
Company Description
Irhythm Technologies
iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.
IRTC Company Deck
IRTC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was constructive and predominantly positive: the company delivered strong top-line growth (≈26% YoY), meaningful margin expansion (880 bps adjusted EBITDA improvement and +210 bps gross margin), raised full‑year revenue and EBITDA guidance, and showed progress on product, AI, clinical evidence, and international commercialization. Offsetting items include continued GAAP/adjusted net losses (though improved), seasonally negative Q1 free cash flow, elevated operating and litigation-related costs, and outstanding regulatory and legal uncertainties (FDA warning letter, DOJ CID) plus potential coverage ambiguity from proposed LCD language. On balance, the operational and commercial positives materially outweigh the remaining execution and regulatory risks.View all IRTC earnings summariesIRTC Stock 12 Month Forecast
Average Price Target
$176.45
▲(40.80% Upside)
Technical Analysis
Ownership Overview
1.84% Insiders
31.24% Mutual Funds
0.12% Other Institutional Investors
51.30% Public Companies and
Individual Investors